Blocking PD-1 or PD-L1 receptors on inactive CD8+ T cells or tumor cells, respectively, increases the influx and activation of CD8+ T cells in the tumor microenvironment that ultimately differentiate into the CTL population for tumor cell killing. Here, CD8A is linked to neoplasm.